Clomiphene 25mg
Clomiphene 25mg is part of a prescriber-directed hormone or endocrine protocol. It should be selected based on symptoms, diagnosis, labs when appropriate, route preference, contraindications, and ongoing monitoring.
Clomiphene 25 mg is a low-dose compounded oral capsule containing clomiphene citrate, a selective estrogen receptor modulator (SERM). Clomiphene competitively blocks hypothalamic estrogen receptors, reducing negative feedback on the hypothalamic-pituitary axis and driving increased secretion of LH and FSH. In men, this raises endogenous testosterone production while preserving the hypothalamic-pituitary-gonadal axis—a key distinction from exogenous testosterone therapy. Genesis Compounding prepares this as a prescription-only 503A compounded oral preparation for patient-specific use; clomiphene is FDA-approved for anovulatory infertility in women and is used off-label in men for secondary hypogonadism.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Clomiphene 25mg | Selective estrogen receptor modulator (SERM) that competitively blocks hypothalamic and pituitary estrogen receptors, removing estradiol-mediated negative feedback and stimulating endogenous LH and FSH secretion, thereby increasing testicular testosterone production in men with secondary hypogonadism. |
Route: Oral (capsule).
- Swallow whole with or without food.
- Take at the same time each day for consistent hormonal stimulation.
- In male hypogonadism protocols, the prescriber will specify daily or alternate-day dosing.
- In female ovulation induction, clomiphene is typically administered on specific cycle days per prescriber instruction.
Dosing is always prescriber-determined based on the indication and individual patient response:
- Off-label male hypogonadism: 25 mg daily or 25 mg every other day is a common starting strategy for secondary hypogonadism. The prescriber adjusts based on testosterone, LH, FSH, and estradiol levels.
- Female ovulation induction: Standard dosing begins at 50 mg/day for 5 days; 25 mg capsules may be used for half-dose regimens or dose tapering.
- Serum testosterone, LH, FSH, and estradiol should guide titration.
- Final dose and schedule are determined by the prescribing clinician.
Clomiphene is a SERM that acts as a competitive estrogen receptor antagonist at the hypothalamus and pituitary. By blocking estradiol's negative feedback effect on pulsatile GnRH release, clomiphene increases LH and FSH pulsatility and amplitude from the anterior pituitary. In men with intact hypothalamic-pituitary-gonadal (HPG) axis function, elevated LH stimulates Leydig cell testosterone synthesis, and elevated FSH supports spermatogenesis. This mechanism preserves testicular function and fertility potential—unlike exogenous testosterone, which suppresses the HPG axis and reduces endogenous production and sperm production.
Clomiphene is FDA-approved for anovulatory/oligo-ovulatory infertility in women (typically 50 mg/day × 5 days). Off-label use in men targets secondary (hypogonadotropic) hypogonadism—defined by low testosterone with inappropriately low or normal LH/FSH. Clomiphene is particularly valuable for men who wish to preserve fertility, as exogenous testosterone suppresses spermatogenesis.
Prescriber monitoring:
- Baseline and follow-up serum total testosterone, LH, FSH, estradiol, and prolactin.
- In women: pelvic exam and pregnancy test before each treatment cycle; monitor for ovarian hyperstimulation syndrome (OHSS).
- Visual symptoms (blurred vision, scotoma) require immediate ophthalmologic evaluation and drug discontinuation.
- Fasting lipids if at risk for hypertriglyceridemia.
- PSA in men over 40 at baseline and with continued use.
Contraindications:
- Pregnancy
- Hepatic disease or history of hepatic impairment
- Hypersensitivity to clomiphene citrate
- Uncontrolled thyroid or adrenal dysfunction
- Ovarian cysts (not related to PCOS) or ovarian enlargement of unknown etiology
- Endometrial carcinoma or estrogen-dependent tumors
- Risk of hypertriglyceridemia
Warnings & Precautions:
- Visual disturbances: promptly discontinue and obtain ophthalmologic evaluation if visual symptoms occur; effects may be irreversible.
- Ovarian hyperstimulation syndrome (OHSS) risk in female patients; can be life-threatening if severe.
- Multiple gestations risk in women.
- Hepatotoxicity reported; do not use in liver disease.
- Long-term use associated with elevated risk of ovarian cancer.
Drug Interactions:
- No established clinically significant drug-drug interactions identified; providers should review all concurrent medications.
Common Side Effects: Vasomotor hot flashes; headache; dizziness; nausea; breast discomfort; visual disturbances (blurring, scintillating scotoma); ovarian enlargement; mood changes; gynecomastia (in men).
Store at controlled room temperature (20–25°C / 68–77°F). Protect from moisture and light. Keep in original container with desiccant if supplied. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.
Why is clomiphene prescribed at 25 mg when the FDA-approved dose is 50 mg?
The FDA-approved 50 mg dose is for female ovulation induction. For off-label use in men with secondary hypogonadism, lower doses (25 mg daily or every other day) are often used to stimulate endogenous testosterone production while minimizing side effects such as estrogen elevation. The prescriber has tailored this dose to the patient's specific hormonal profile and goals.
How is clomiphene different from testosterone replacement therapy?
Exogenous testosterone suppresses the body's own LH and FSH, shutting down natural testosterone production and spermatogenesis—often causing testicular atrophy. Clomiphene works upstream by blocking estrogen feedback at the brain, stimulating the body to produce its own testosterone while preserving fertility. It is preferred when maintaining sperm production is a clinical goal.
Is this product FDA-approved?
Clomiphene citrate is FDA-approved for female anovulatory infertility. Its use in male hypogonadism is off-label. This 25 mg capsule is a 503A compounded preparation from Genesis Compounding for a specific patient—not an FDA-approved product at this dosage form.
What blood tests should be monitored during treatment?
Your prescriber will typically check serum total testosterone, LH, FSH, estradiol, and prolactin at baseline and after initiating therapy to assess response and guide dose adjustments. Visual symptoms require immediate evaluation regardless of lab values.
What should I do if I notice visual changes?
Stop taking clomiphene immediately and contact your prescriber and an ophthalmologist. Visual disturbances—including blurred vision, flashes, or scotomas—can occur and may become irreversible if the drug is not discontinued promptly.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.